(Q38041983)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Understanding and learning from the success of prophylactic human papillomavirus vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

John T Schiller

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Douglas R Lowy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

10 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Microbiology

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

681-692

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrmicro2872

12 February 2020

exact match

0 references

cites work

The perpetual challenge of infectious diseases.

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The cervical cancer epidemic that screening has prevented in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Oncogenic activities of human papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The papillomavirus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The coming of age of virus-like particle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Duration of humoral immunity to common viral and vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Genome variation of human papillomavirus types: phylogenetic and medical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

In vivo mechanisms of vaccine-induced protection against HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Immunobiology of HPV and HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

HIV vaccine development at the turn of the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

HSV-2: in pursuit of a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Developments in virus-like particle-based vaccines for infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Distribution and three-dimensional structure of AIDS virus envelope spikes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Primary human epithelial cell culture system for studying interactions between female upper genital tract and sexually transmitted viruses, HSV-2 and HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

HIV infection of the genital mucosa in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The role of antibodies in HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Genital transmission of human papillomavirus in recently formed heterosexual couples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Strategies for eliciting HIV-1 inhibitory antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The influence of virus structure on antibody responses and virus serotype formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Herpes simplex virus infects most cell types in vitro: clues to its success

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Efficacy results of a trial of a herpes simplex vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Efficient intracellular assembly of papillomaviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

The influence of antigen organization on B cell responsiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2872

Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind

31 March 2020

1 reference

12 December 2020

The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors.

1 reference

12 December 2020

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

12 December 2020

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

1 reference

12 December 2020

Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles

1 reference

12 December 2020

In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRMICRO2872

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22961341%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

22961341

1 reference